vk2735 news - Search News

Viking, VK2735

Seeking Alpha · 1d

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term prospects remain positive.

Business Insider · 1d

Viking Therapeutics Stock Climbs On Positive Data From VK2735 Obesity Program

Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company

Kiplinger on MSN · 1d

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

17hon MSN

Is Viking Therepautics a Buy Now?

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

GlobalData on MSN11h

Viking stock fluctuates amid manufacturing concerns with obesity pill

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

1d

Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety

Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...

1d

Wall Street Lunch: Viking Weight-Loss Pill Data Is Striking

Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...

1d

Viking rises after 'competitive' efficacy, safety data from oral weight-loss drug

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results